AnaptysBio, Inc.

Equities

ANAB

US0327241065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 22/05/2024 BST			5-day change	1st Jan Change
25.04 ^USD	+4.55%		-2.19%	+16.90%

05-09	AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-09	Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis	CI

AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 09, 2024 at 09:24 pm

AnaptysBio, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 43.94 million compared to USD 44.26 million a year ago. Basic loss per share from continuing operations was USD 1.64 compared to USD 1.58 a year ago.

Diluted loss per share from continuing operations was USD 1.64 compared to USD 1.58 a year ago.

Latest news about AnaptysBio, Inc.

AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis	05-09	CI
Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	04-16	MT
Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	04-11	MT
JPMorgan Adjusts Price Target on AnaptysBio to $28 From $30, Maintains Neutral Rating	04-01	MT
AnaptysBio, Inc.(NasdaqGS:ANAB) added to S&P Biotechnology Select Industry Index	03-17	CI
North American Morning Briefing : Stock Futures -2-	03-13	DJ
AnaptysBio Shares Jump on Upgrade by Wedbush	03-12	MT
Wedbush Upgrades AnaptysBio to Outperform From Neutral, Says Derivative, Clinical Catalysts to Drive Shares Higher; Raises PT to $34 From $20	03-12	MT
AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-11	CI
BTIG Initiates Coverage on AnaptysBio With Buy Rating, $55 Price Target	02-26	MT
AnaptysBio Shares Climb as Piper Sandler Starts Coverage With Overweight Rating	02-16	MT
Piper Sandler Initiates AnaptysBio at Overweight Rating With $80 Price Target	02-16	MT
AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from S&P Biotechnology Select Industry Index	12-18	CI
GSK: EU approves Jemperli for endometrial cancer	12-11	CF
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio	11-27	MT
Wedbush Lifts AnaptysBio's PT to $20 From $18 Due to Updated Cash Guidance, Keeps Neutral Rating	11-03	MT
AnaptysBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
UBS Cuts AnaptysBio Price Target to $21 From $28, Maintains Neutral Rating	11-01	MT
Wedbush Lowers AnaptysBio's PT to $18 From $26, Adjusts Launch Estimates, Addition of Ulcerative Colitis for Rosnilimab; Keeps Neutral Rating	26/10/23	MT
Transcript : AnaptysBio, Inc. - Special Call	25/10/23
AnaptysBio's Phase 3 Trial of Imsidolimab to Treat Generalized Pustular Psoriasis Meets Primary Endpoint	09/10/23	MT
Anaptys Sees Positive Trial Results for Imsidolimad Psoriasis Treatment	09/10/23	DJ
AnaptysBio's skin disease drug meets main goal in late-stage study	09/10/23	RE

Chart AnaptysBio, Inc.

Duration

Period

More charts

Company Profile

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.

Sector

Biotechnology & Medical Research

Calendar

12/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for AnaptysBio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.04 USD

Average target price

43.78 USD

Spread / Average Target

+74.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANAPTYSBIO, INC.	+16.90%	684M
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	115B
REGENERON PHARMACEUTICALS, INC.	+12.01%	106B
BIONTECH SE	-3.07%	24.69B
ARGENX SE	-0.58%	21.97B
GENMAB A/S	-5.10%	19.27B
BEIGENE, LTD.	-6.90%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	14.03B
SAREPTA THERAPEUTICS, INC.	+33.05%	12.13B

Bio Therapeutic Drugs